The Vacaville facility currently has a total bioreactor capacity of around 330,000 liters, making it one of the largest biologics ... offered employment by Lonza and the products currently ...

Investing.com -- Lonza Group AG (SWX:LONN) today unveiled its comparative financials for its newly implemented operating model, ’One Lonza’, for the fiscal year 2024 and the first half of 2024, ahead ...

with biologics and cell and gene therapies playing larger roles in the overall mix, and Lonza has been investing heavily in new manufacturing capabilities. We sell different types of products and ...

Lonza’s biologics segment accounted for 51% of its ... Due to the high switching costs, Lonza manufactures products for the entirety of their commercial life, which is often around 10 years.

The state’s largest pharma manufacturer – Lonza Biologics in Portsmouth – is in the process ... With their partners they are developing products that will forever change healthcare. Buildings are one ...

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical ... It operates through Biologics; Small Molecules; Cell & Gene; and Capsules & Health ...

Wolfgang Weinand, CEO of Lonza, said the firm is excited to take the step to increase its capacity to create products in the ... the Vacaville site joins our Biologics division, we look forward ...

Lonza completed its acquisition of the ... to meet demand for the next generation of mammalian biologics therapies. The products previously manufactured at the site will now be supplied by Lonza ...

Jean-Christophe Hyvert, President, Biologics, Lonza, added: "We are pleased to ... an antibody to develop proprietary best-in-class ADC products under a single license from Synaffix.

The Vacaville facility currently has a total bioreactor capacity of around 330,000 litres, making it one of the largest biologics manufacturing ... the facility will be offered employment by Lonza, ...

(Reuters) -Swiss contract drug manufacturer Lonza said on Wednesday it would buy one of the world's largest manufacturing sites for biologic drugs in California from drugmaker Roche for $1.2 billion.